

# Regression of Intracranial Meningiomas Following Treatment with Cabozantinib

Rupesh Kotecha, Raees Tonse, Haley Appel, Yazmin Odia, Ritesh R. Kotecha, Guilherme Rabinowits and Minesh P. Mehta

**Table S1.** Ongoing trials of VEGF agents in meningioma patients.

Trial Registration Number	Regimen	Mechanism of Action	Study Design	Number of Patients	WHO Grade Inclusion	Primary End Point*	Estimated Primary Completion Date
NCT01125046	Bevacizumab	Anti-VEGF antibody	Phase II	50	I/II/III	PFS - 6 Months	Jul-19
NCT02847559	Bevacizumab + Optune	Anti-VEGF antibody, Electric Field therapy	Phase II	27	II/III	PFS - 6 Months	Sep-21
NCT03279692	Pembrolizumab	PD-1 inhibitor	Phase II	26	II/III	PFS - 6 Months	Sep-25

\* 6-month progression-free survival.

**Table S2.** – Select clinical studies evaluating Cabozantinib in patients with primary or metastatic CNS tumors.

Author and year	Regimen	Study Design	Number of Patients	Diagnosis
Wen et al., 2017 <sup>17</sup>	Cabozantinib	Phase II	152	Recurrent Glioblastoma
Cloughesy et al., 2018 <sup>16</sup>	Cabozantinib	Phase II	222	Recurrent Glioblastoma